As of 2026-03-21, the Relative Valuation of Y-mAbs Therapeutics, Inc (YMAB) is (11.27) USD. This relative valuation is based on P/E multiples. With the latest stock price at 8.61 USD, the upside of Y-mAbs Therapeutics, Inc based on Relative Valuation is -230.9%.
The range of the Relative Valuation is (10.20) - (13.17) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 20.9x - 28.2x | 24.3x |
| Forward P/E multiples | 20.7x - 26.9x | 21.8x |
| Fair Price | (10.20) - (13.17) | (11.27) |
| Upside | -218.5% - -252.9% | -230.9% |
| Date | P/E |